Most Favored Nation pricing in the US
At the 2026 JP Morgan Healthcare Conference, CRA hosted an expert panel session with health policy experts from the US, Germany, and the UK to discuss the...
This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
For more than 25 years, life science companies, law firms, and regulatory agencies around the globe have turned to CRA’s life sciences consultants when they need clarity and solutions to the industry’s most complex issues. Clients value our deep industry knowledge, rigorous analytic techniques, and decades of hands-on experience spanning thousands of successful engagements.
At the 2026 JP Morgan Healthcare Conference, CRA hosted an expert panel session with health policy experts from the US, Germany, and the UK to discuss the...
The National Healthcare Security Administration (NHSA) engages clinical and negotiation experts to assess manufacturer submissions and establish a list of...
Last year, Regeneron took to trial its case alleging exclusionary conduct through bundled rebates by competitor Amgen. The jury found for Regeneron, awarding...
CRA is a proud sponsor of Europe’s largest congress in market access, pricing and evidence featuring 250 speakers, 10 tracks and 1500+ attendees from pharma,...
CRA is a proud sponsor of the event, back for its 8th edition. This half-day, high-impact conference brings together top arbitrators, counsel, experts and...
The U.S. Most Favored Nation (MFN) Executive Order could upend global drug pricing as we know it. Some manufacturers are now vowing to launch only at U.S....
